Kymera Therapeutics, Inc. $KYMR Stock Sold by Moody Aldrich Partners LLC

Key Points

• Moody Aldrich Partners cut its Kymera Therapeutics stake by 28.9% in the third quarter, selling 8,685 shares and retaining 21,321 shares valued at approximately $2.38 million.
• Kymera insiders also sold shares, including CEO Nello Mainolfi’s $3.41 million transaction, while other institutional investors increased their positions. Insiders currently own 15.98% of the company.
• Analysts remain broadly bullish, with a “Moderate Buy” consensus and an average price target of $135.12. KYMR opened at $122.51, while the company reported better-than-expected quarterly revenue and EPS despite continuing losses.

Moody Aldrich Partners LLC reduced its stake in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 28.9% during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 21,321 shares of the company's stock after selling 8,685 shares during the period. Moody Aldrich Partners LLC's holdings in Kymera Therapeutics were worth $2,383,000 as of its most recent filing with the SEC.

Other institutional investors have also recently bought and sold shares of the company. Sterling Capital Management LLC boosted its holdings in shares of Kymera Therapeutics by 378.6% in the third quarter. Sterling Capital Management LLC now owns 1,919 shares of the company's stock valued at $215,000 after buying an additional 1,518 shares during the period. Inspire Investing LLC bought a new stake in shares of Kymera Therapeutics during the third quarter worth $482,000. Nisa Investment Advisors LLC raised its holdings in shares of Kymera Therapeutics by 45.9% during the third quarter. Nisa Investment Advisors LLC now owns 2,073 shares of the company's stock worth $232,000 after acquiring an additional 652 shares during the period. Abel Hall LLC raised its holdings in shares of Kymera Therapeutics by 4.0% during the third quarter. Abel Hall LLC now owns 4,870 shares of the company's stock worth $544,000 after acquiring an additional 189 shares during the period. Finally, IFP Advisors Inc raised its holdings in shares of Kymera Therapeutics by 236.5% during the third quarter. IFP Advisors Inc now owns 737 shares of the company's stock worth $82,000 after acquiring an additional 518 shares during the period.

Insider Buying and Selling at Kymera Therapeutics

In other Kymera Therapeutics news, insider Brian Adams sold 6,371 shares of Kymera Therapeutics stock in a transaction on Friday, September 4th. The shares were sold at an average price of $116.83, for a total value of $744,323.93. Following the sale, the insider directly owned 50,254 shares in the company, valued at approximately $5,871,174.82. The trade was a 11.25% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Nello Mainolfi sold 30,000 shares of the business's stock in a transaction dated Thursday, October 1st. The stock was sold at an average price of $113.80, for a total transaction of $3,414,000.00. Following the sale, the chief executive officer directly owned 666,568 shares in the company, valued at $75,855,438.40. This trade represents a 4.31% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 15.98% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on KYMR shares. Deutsche Bank Aktiengesellschaft began coverage on shares of Kymera Therapeutics in a research report on Thursday, July 30th. They issued a "hold" rating and a $120.00 price objective on the stock. Morgan Stanley increased their target price on Kymera Therapeutics from $135.00 to $146.00 and gave the stock an "overweight" rating in a report on Tuesday. Citigroup lifted their price target on Kymera Therapeutics from $135.00 to $150.00 and gave the company a "buy" rating in a research note on Monday, October 5th. TD Cowen raised Kymera Therapeutics to a "strong-buy" rating in a research note on Monday, August 24th. Finally, Raymond James Financial started coverage on Kymera Therapeutics in a report on Thursday, October 8th. They issued an "outperform" rating and a $140.00 price target on the stock. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $135.12.

Kymera Therapeutics Stock Up 4.2%

NASDAQ:KYMR opened at $122.51 on Thursday. The company has a market cap of $10.19 billion, a P/E ratio of -37.81 and a beta of 1.98. Kymera Therapeutics, Inc. has a twelve month low of $55.66 and a twelve month high of $130.05. The business has a 50 day moving average price of $114.92 and a two-hundred day moving average price of $95.84.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last posted its quarterly earnings data on Wednesday, August 5th. The company reported ($0.62) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.71) by $0.09. Kymera Therapeutics had a negative net margin of 285.33% and a negative return on equity of 21.22%. The company had revenue of $65.00 million for the quarter, compared to the consensus estimate of $32.78 million. During the same period last year, the company earned ($0.95) earnings per share. The firm's revenue was up 465.2% compared to the same quarter last year. As a group, analysts anticipate that Kymera Therapeutics, Inc. will post -3.85 earnings per share for the current fiscal year.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical-stage biotechnology company focused on developing medicines that selectively eliminate disease-causing proteins through targeted protein degradation. Its approach is designed to use the cell's natural protein-disposal system to remove proteins that may be difficult to address with conventional drug modalities.

The company's research and development programs have targeted a range of disease areas, including immune-mediated and inflammatory conditions, cancer, and other serious illnesses.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.